# AN2 Therapeutics, Inc.: filings

ANTX · Nasdaq · CIK 1880438 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/antx.md) · [Financials](/companies/antx/financials.md) · [Filings](/companies/antx/filings.md) · [Insiders](/companies/antx/insiders.md)

## Reports and events: 68 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 186, 8-K 40, 3 21, 10-Q 14, 144 14, SC 13G/A 14, SC 13G 11, SCHEDULE 13G/A 9, 4/A 7, S-8 6, SCHEDULE 13G 6, 10-K 4, ARS 4, CORRESP 4, DEF 14A 4, DEFA14A 4, UPLOAD 4, 424B5 3, EFFECT 3, 8-A12B 2, DRS/A 2, DRSLTR 2, S-3 2, SCHEDULE 13D/A 2, SEC STAFF LETTER 2, 10-K/A 1, 3/A 1, 424B3 1, 424B4 1, CERT 1, D 1, DRS 1, PRE 14A 1, S-1 1, S-1/A 1, S-1MEF 1, SCHEDULE 13D 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-11 | 20:04 ET | [10-Q](/filings/0001193125-26-344569.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344569 |
| 2026-08-11 | 20:01 ET | [8-K](/filings/0001193125-26-344549.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344549 |
| 2026-06-09 | 22:23 ET | [8-K](/filings/0001193125-26-262264.md) | 5.07 Shareholder vote results | 0001193125-26-262264 |
| 2026-06-04 | 20:15 ET | [8-K](/filings/0001193125-26-257430.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-257430 |
| 2026-05-11 | 20:08 ET | [10-Q](/filings/0001193125-26-216755.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216755 |
| 2026-05-11 | 20:06 ET | [8-K](/filings/0001193125-26-216752.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216752 |
| 2026-04-22 | 20:01 ET | [DEF 14A](/filings/0001193125-26-170314.md) | Proxy statement, period 2026-04-22 | 0001193125-26-170314 |
| 2026-04-09 | 21:03 ET | [8-K](/filings/0001193125-26-149822.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-149822 |
| 2026-03-20 | 20:37 ET | [8-K](/filings/0001193125-26-117765.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-117765 |
| 2026-03-17 | 20:03 ET | [10-K](/filings/0001193125-26-110693.md) | Annual report, period 2025-12-31 | 0001193125-26-110693 |
| 2026-03-17 | 20:02 ET | [8-K](/filings/0001193125-26-110681.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-110681 |
| 2026-03-10 | 01:43 ET | [8-K](/filings/0001193125-26-099169.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-099169 |
| 2026-01-29 | 21:45 ET | [8-K](/filings/0001193125-26-029540.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-029540 |
| 2025-11-12 | 21:21 ET | [10-Q](/filings/0001193125-25-277673.md) | Quarterly report, period 2025-09-30 | 0001193125-25-277673 |
| 2025-11-12 | 21:19 ET | [8-K](/filings/0001193125-25-277662.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277662 |
| 2025-08-12 | 20:06 ET | [10-Q](/filings/0000950170-25-107301.md) | Quarterly report, period 2025-06-30 | 0000950170-25-107301 |
| 2025-08-12 | 20:02 ET | [8-K](/filings/0000950170-25-107278.md) | 9.01 Financial statements and exhibits | 0000950170-25-107278 |
| 2025-06-20 | 11:00 ET | [8-K](/filings/0001193125-25-143187.md) | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-143187 |
| 2025-06-18 | 15:08 ET | [SCHEDULE 13D/A](/filings/0001373604-25-000092.md) | Ownership report, active investor, amended | 0001373604-25-000092 |
| 2025-06-11 | 11:30 ET | [8-K](/filings/0001193125-25-138796.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-138796 |
| 2025-05-30 | 21:46 ET | [SCHEDULE 13D/A](/filings/0001373604-25-000086.md) | Ownership report, active investor, amended | 0001373604-25-000086 |
| 2025-05-27 | 20:30 ET | [8-K](/filings/0001193125-25-127595.md) | 5.07 Shareholder vote results | 0001193125-25-127595 |
| 2025-05-13 | 20:12 ET | [10-Q](/filings/0000950170-25-070358.md) | Quarterly report, period 2025-03-31 | 0000950170-25-070358 |
| 2025-05-13 | 20:05 ET | [8-K](/filings/0000950170-25-070305.md) | 9.01 Financial statements and exhibits | 0000950170-25-070305 |
| 2025-05-07 | 14:27 ET | [SCHEDULE 13D](/filings/0001373604-25-000074.md) | Ownership report, active investor | 0001373604-25-000074 |
| 2025-05-01 | 20:27 ET | [8-K](/filings/0001193125-25-110019.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-110019 |
| 2025-04-10 | 20:05 ET | [DEF 14A](/filings/0000950170-25-052852.md) | Proxy statement, period 2025-04-10 | 0000950170-25-052852 |
| 2025-03-25 | 20:07 ET | [10-K](/filings/0000950170-25-044366.md) | Annual report, period 2024-12-31 | 0000950170-25-044366 |
| 2025-03-25 | 20:03 ET | [8-K](/filings/0000950170-25-044353.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-044353 |
| 2024-11-13 | 21:04 ET | [10-Q](/filings/0000950170-24-126282.md) | Quarterly report, period 2024-09-30 | 0000950170-24-126282 |
| 2024-11-13 | 21:02 ET | [8-K](/filings/0000950170-24-126276.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126276 |
| 2024-11-05 | 21:05 ET | [8-K](/filings/0001193125-24-251240.md) | 5.02 Departure or appointment of officers or directors | 0001193125-24-251240 |
| 2024-08-19 | 10:04 ET | [8-K](/filings/0001193125-24-202430.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-202430 |
| 2024-08-13 | 20:15 ET | [10-Q](/filings/0000950170-24-096243.md) | Quarterly report, period 2024-06-30 | 0000950170-24-096243 |
| 2024-08-13 | 20:06 ET | [8-K](/filings/0000950170-24-096173.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096173 |
| 2024-08-08 | 20:50 ET | [8-K](/filings/0001193125-24-197047.md) | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-197047 |
| 2024-06-24 | 20:06 ET | [8-K](/filings/0001193125-24-166938.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-166938 |
| 2024-05-14 | 20:12 ET | [10-Q](/filings/0000950170-24-059556.md) | Quarterly report, period 2024-03-31 | 0000950170-24-059556 |
| 2024-05-14 | 20:07 ET | [8-K](/filings/0000950170-24-059527.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-059527 |
| 2024-05-14 | 20:01 ET | [10-K/A](/filings/0000950170-24-059488.md) | Annual report, amended, period 2023-12-31 | 0000950170-24-059488 |
| 2024-04-26 | 20:15 ET | [DEF 14A](/filings/0000950170-24-049148.md) | Proxy statement, period 2024-06-19 | 0000950170-24-049148 |
| 2024-03-29 | 20:24 ET | [10-K](/filings/0000950170-24-038681.md) | Annual report, period 2023-12-31 | 0000950170-24-038681 |
| 2024-03-28 | 20:15 ET | [8-K](/filings/0000950170-24-038055.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-038055 |
| 2024-02-12 | 12:01 ET | [8-K](/filings/0001193125-24-031008.md) | 8.01 Other events | 0001193125-24-031008 |
| 2023-11-09 | 21:15 ET | [10-Q](/filings/0000950170-23-062081.md) | Quarterly report, period 2023-09-30 | 0000950170-23-062081 |
| 2023-11-09 | 21:10 ET | [8-K](/filings/0000950170-23-062046.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062046 |
| 2023-09-13 | 12:00 ET | [8-K](/filings/0001193125-23-233934.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-233934 |
| 2023-09-08 | 21:37 ET | [8-K](/filings/0001193125-23-230786.md) | 5.02 Departure or appointment of officers or directors | 0001193125-23-230786 |
| 2023-08-16 | 20:47 ET | [8-K](/filings/0001193125-23-214362.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-214362 |
| 2023-08-10 | 20:25 ET | [10-Q](/filings/0000950170-23-041378.md) | Quarterly report, period 2023-06-30 | 0000950170-23-041378 |

Page 1 of 2. [Older](/companies/antx/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. No prices; not investment advice.